How you can complete the Cologuard order on the web: To begin the blank, utilize the Fill & Sign Online button or tick the preview image of the document. The advanced tools of the editor will lead you through the editable PDF template. Enter your official identification and contact details. Utilize a check mark to point the choice wherever required. More items...
Health Tradition members who are 50 to 75 years of age are eligible for Cologuard. Cologuard may not be appropriate for everyone based on specific health factors or conditions. Talk to your doctor to see if Cologuard is right for you.
Colon cancer screening has a small benefit, overall, one of the few that does. A screening test, like FIT or cologuard, should be most reliable when it's negative, so we don't miss true disease very often.
The Cologuard test is a stool DNA test that looks for microscopic blood in the stool and altered DNA . It's performed using an at-home kit that includes a container for a stool sample. That sample is then shipped to a lab for testing. How Accurate is the Cologuard test? Cologuard can detect 92% of cancers but only 42% of large precancerous polyps.
How do I get my Cologuard results? Cologuard will send your results directly to your provider two weeks after your kit is sent in. The results will be posted to the Patient Portal.
1-844-870-8870Call 1-844-870-8870 Our Customer Care Center is available 24/7.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Exact Sciences is the maker of Cologuard, an at-home colon cancer screening test, as well as a diagnostic test used by doctors to individualize cancer treatments. The company relocated their headquarters to Madison in 2009 and currently employs around 3,500 people there.
Call 1-844-870-8870 for help or schedule a pick-up now.
Cologuard is covered by Medicare and Medicare Advantage with no co-pay or deductible for eligible patients ages 50-85.
I feel most gastroenterologists would agree Cologuard is a potent weapon in the armamentarium against colon cancer. The 92 percent sensitivity for CRC, and 69 percent sensitivity for detection adenomas with high grade dysplasia, make it the standard second line option, next to colonoscopy.
Cologuard's accuracy rate for detecting colorectal cancers and precancerous polyps is touted to be 92%. While that is impressive for a stool-based test, it still means that 8% of lesions will go undetected, leaving those patients with a false sense of security. Cologuard has a 14% false-positive rate.
Pfizer sales representatives to co-promote Exact Sciences' Cologuard test in multimillion-dollar deal. Pfizer signed a three-year agreement to co-promote Exact Sciences' Cologuard stool DNA screening test for colorectal cancer, committing to spend a total of about $70 million on marketing expenses through December 2021 ...
The cost of Cologuard is around $500. Part of that cost may be covered by some insurances depending on your plan, co-pay, and deductible. Diagnostic testing is subject to deductibles and coinsurance. Screening colonoscopies are not subject to copays and deductibles and usually have no out-of-pocket costs for patients.
Exact Sciences (company)Innovation One, the headquarters of Exact Sciences in Madison, Wisconsin (2020).Founded1995 in Marlborough, MassachusettsFoundersStanley Lapidus Anthony P. ShuberHeadquartersMadison, Wisconsin, U.S.Key peopleKevin Conroy (Chairman, President & CEO) Jorge Garces (Chief Science Officer)13 more rows
Two years ago this month, the Food and Drug Administration approved Exact Sciences' Cologuard. The news on August 11, 2014 made Cologuard the first and only FDA-approved stool DNA screening test for colorectal cancer.
Positive Result. The test detected altered DNA and/or blood that could be caused by a precancerous polyp or colon cancer. Any positive result should be discussed with a healthcare provider and followed up with a diagnostic colonoscopy.
False negatives do occur. A false negative result occurs when Cologuard does not detect a precancerous polyp or colon cancer even when a colonoscopy identifies the positive result.
Cologuard is an effective, noninvasive CRC screening option for patients aged 45 years and older at average risk. 2. Cologuard ® is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool.
A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma (AA) and should be followed by diagnostic colonoscopy. Cologuard is indicated to screen adults of either sex, 45 years or older, who are at typical average risk for CRC.
Cologuard is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. Cologuard is not for high-risk individuals, including patients with a personal history of colorectal cancer and adenomas; have had a positive result from another colorectal cancer screening method within the last 6 months;
A negative Cologuard test result does not guarantee absence of cancer or advanced adenoma. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. False positives and false negatives do occur. In a clinical study, 13% of patients without ...
This proprietary technology proved to be a breakthrough in the development of the multitarget stool DNA test. Our scientists needed to first solve the essential problem of effectively isolating DNA from stool before achieving the goal of developing a noninvasive colon cancer screening test.
The development of an enhanced DNA stabilizing buffer was a critical step in the process of creating a reliable at-home screening kit. With this advance, the DNA in stool samples is protected through the transport process and remains amenable to analysis once it arrives at our processing center.
We developed our proprietary QuARTS technology (Quantitative Allele-specific Real-time Target and Signal Amplification) which efficiently amplifies and quantifies two separate methylated DNA markers (NDRG4 and BMP3) along with seven distinct KRAS gene point mutations.
We improved upon the technology for the ELISA-based detection of a protein biomarker (hemoglobin) through an additive in the stabilization buffer. This innovation allows for longer transit time from sample collection to processing by the lab.
The final step in the multitarget stool DNA test incorporates the quantitative results from the DNA alterations combined with the protein biomarker detection to determine a positive or negative result. This algorithm is the vital workhorse that translates our invisible biology into actionable information.